{"id":2310,"date":"2015-05-01T19:55:11","date_gmt":"2015-05-01T19:55:11","guid":{"rendered":"https:\/\/www.lymphoma.ca\/zydelig-idelalisib-recoit-lapprobation-par-sante-canada-pour-le-traitement-de-la-llc-et-du-lymphome-folliculaire\/"},"modified":"2015-05-01T19:55:11","modified_gmt":"2015-05-01T19:55:11","slug":"zydelig-idelalisib-recoit-lapprobation-par-sante-canada-pour-le-traitement-de-la-llc-et-du-lymphome-folliculaire","status":"publish","type":"post","link":"https:\/\/www.lymphoma.ca\/fr\/zydelig-idelalisib-recoit-lapprobation-par-sante-canada-pour-le-traitement-de-la-llc-et-du-lymphome-folliculaire\/","title":{"rendered":"ZYDELIG (id\u00e9lalisib) re\u00e7oit l\u2019approbation par Sant\u00e9 Canada pour le traitement de la LLC et du lymphome folliculaire"},"content":{"rendered":"<div class=\"field field-name-body field-type-text-with-summary field-label-hidden\">\n<div class=\"field-items\">\n<div class=\"field-item even\">\n<h2>Sant\u00e9 Canada approuve ZYDELIG (id\u00e9lalisib), de Gilead, pour le traitement de la leuc\u00e9mie lympho\u00efde chronique (LLC) r\u00e9cidivante et approuve ZYDELIG sous condition pour le traitement du lymphome folliculaire<\/h2>\n<p><span>8 avril 2015<br \/><\/span><\/p>\n<p>Gilead&nbsp; Sciences&nbsp; Canada,&nbsp; Inc.&nbsp; a&nbsp; annonc\u00e9 l&rsquo;\u00e9mission&nbsp; par&nbsp; Sant\u00e9&nbsp; Canada&nbsp; d&rsquo;un&nbsp; avis&nbsp; de&nbsp; conformit\u00e9&nbsp; pour&nbsp; ZYDELIG (id\u00e9lalisib)&nbsp; en&nbsp; comprim\u00e9&nbsp; en&nbsp; association avec le rituximab pour le traitement des patients atteints d&rsquo;une leuc\u00e9mie lympho\u00efde chronique (LLC)&nbsp; r\u00e9cidivante.&nbsp;&nbsp; Une&nbsp; autorisation&nbsp; de commercialisation avec&nbsp; conditions&nbsp; a&nbsp; aussi&nbsp; \u00e9t\u00e9 obtenu&nbsp; pour ZYDELIG&nbsp; en&nbsp; monoth\u00e9rapie&nbsp; pour&nbsp; le&nbsp; traitement&nbsp; des&nbsp; patients&nbsp; atteints&nbsp; d&rsquo;un&nbsp; lymphome&nbsp; folliculaire&nbsp; (LF) r\u00e9cidivant ayant d\u00e9j\u00e0 re\u00e7u au moins deux r\u00e9gimes th\u00e9rapeutiques syst\u00e9miques et r\u00e9fractaires \u00e0 la fois au rituximab et \u00e0 un agent alkylant.&nbsp; ZYDELIG est le premier m\u00e9dicament de la classe des inhibiteurs de la PI3K delta. La PI3K delta est une prot\u00e9ine qui est surexprim\u00e9e dans de nombreux cancers \u00e0 cellules B et qui joue un r\u00f4le dans la survie, la prolif\u00e9ration et la migration de ces cellules canc\u00e9reuses.<\/p>\n<p><a title=\"zydelig ressources\" href=\"https:\/\/www.lymphoma.ca\/wp-content\/uploads\/2015\/05\/zydelig_fr_april_30.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Cliquez ici<\/a> pour lire le communiqu\u00e9 de presse complet.<\/p>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Sant\u00e9 Canada approuve ZYDELIG (id\u00e9lalisib), de Gilead, pour le traitement de la leuc\u00e9mie lympho\u00efde chronique (LLC) r\u00e9cidivante et approuve ZYDELIG sous condition pour le traitement du lymphome folliculaire 8 avril&#8230;<\/p>\n","protected":false},"author":1,"featured_media":1772,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[10],"tags":[],"class_list":{"0":"post-2310","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-nouvelles"},"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.7 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>ZYDELIG (id\u00e9lalisib) re\u00e7oit l\u2019approbation par Sant\u00e9 Canada pour le traitement de la LLC et du lymphome folliculaire - Lymphoma Canada<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.lymphoma.ca\/fr\/zydelig-idelalisib-recoit-lapprobation-par-sante-canada-pour-le-traitement-de-la-llc-et-du-lymphome-folliculaire\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ZYDELIG (id\u00e9lalisib) re\u00e7oit l\u2019approbation par Sant\u00e9 Canada pour le traitement de la LLC et du lymphome folliculaire - Lymphoma Canada\" \/>\n<meta property=\"og:description\" content=\"Sant\u00e9 Canada approuve ZYDELIG (id\u00e9lalisib), de Gilead, pour le traitement de la leuc\u00e9mie lympho\u00efde chronique (LLC) r\u00e9cidivante et approuve ZYDELIG sous condition pour le traitement du lymphome folliculaire 8 avril...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.lymphoma.ca\/fr\/zydelig-idelalisib-recoit-lapprobation-par-sante-canada-pour-le-traitement-de-la-llc-et-du-lymphome-folliculaire\/\" \/>\n<meta property=\"og:site_name\" content=\"Lymphoma Canada\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/LymphomaCanada\" \/>\n<meta property=\"article:published_time\" content=\"2015-05-01T19:55:11+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.lymphoma.ca\/wp-content\/uploads\/2013\/04\/masthead_ph_shadows.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"700\" \/>\n\t<meta property=\"og:image:height\" content=\"300\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@lymphomacanada\" \/>\n<meta name=\"twitter:site\" content=\"@lymphomacanada\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.lymphoma.ca\/fr\/zydelig-idelalisib-recoit-lapprobation-par-sante-canada-pour-le-traitement-de-la-llc-et-du-lymphome-folliculaire\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.lymphoma.ca\/fr\/zydelig-idelalisib-recoit-lapprobation-par-sante-canada-pour-le-traitement-de-la-llc-et-du-lymphome-folliculaire\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\/\/www.lymphoma.ca\/fr\/#\/schema\/person\/3f654528f96ee33030061e70192633c4\"},\"headline\":\"ZYDELIG (id\u00e9lalisib) re\u00e7oit l\u2019approbation par Sant\u00e9 Canada pour le traitement de la LLC et du lymphome folliculaire\",\"datePublished\":\"2015-05-01T19:55:11+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.lymphoma.ca\/fr\/zydelig-idelalisib-recoit-lapprobation-par-sante-canada-pour-le-traitement-de-la-llc-et-du-lymphome-folliculaire\/\"},\"wordCount\":253,\"publisher\":{\"@id\":\"https:\/\/www.lymphoma.ca\/fr\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.lymphoma.ca\/fr\/zydelig-idelalisib-recoit-lapprobation-par-sante-canada-pour-le-traitement-de-la-llc-et-du-lymphome-folliculaire\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.lymphoma.ca\/wp-content\/uploads\/2013\/04\/masthead_ph_shadows.jpg\",\"articleSection\":[\"Nouvelles\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.lymphoma.ca\/fr\/zydelig-idelalisib-recoit-lapprobation-par-sante-canada-pour-le-traitement-de-la-llc-et-du-lymphome-folliculaire\/\",\"url\":\"https:\/\/www.lymphoma.ca\/fr\/zydelig-idelalisib-recoit-lapprobation-par-sante-canada-pour-le-traitement-de-la-llc-et-du-lymphome-folliculaire\/\",\"name\":\"ZYDELIG (id\u00e9lalisib) re\u00e7oit l\u2019approbation par Sant\u00e9 Canada pour le traitement de la LLC et du lymphome folliculaire - Lymphoma Canada\",\"isPartOf\":{\"@id\":\"https:\/\/www.lymphoma.ca\/fr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.lymphoma.ca\/fr\/zydelig-idelalisib-recoit-lapprobation-par-sante-canada-pour-le-traitement-de-la-llc-et-du-lymphome-folliculaire\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.lymphoma.ca\/fr\/zydelig-idelalisib-recoit-lapprobation-par-sante-canada-pour-le-traitement-de-la-llc-et-du-lymphome-folliculaire\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.lymphoma.ca\/wp-content\/uploads\/2013\/04\/masthead_ph_shadows.jpg\",\"datePublished\":\"2015-05-01T19:55:11+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.lymphoma.ca\/fr\/zydelig-idelalisib-recoit-lapprobation-par-sante-canada-pour-le-traitement-de-la-llc-et-du-lymphome-folliculaire\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.lymphoma.ca\/fr\/zydelig-idelalisib-recoit-lapprobation-par-sante-canada-pour-le-traitement-de-la-llc-et-du-lymphome-folliculaire\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.lymphoma.ca\/fr\/zydelig-idelalisib-recoit-lapprobation-par-sante-canada-pour-le-traitement-de-la-llc-et-du-lymphome-folliculaire\/#primaryimage\",\"url\":\"https:\/\/www.lymphoma.ca\/wp-content\/uploads\/2013\/04\/masthead_ph_shadows.jpg\",\"contentUrl\":\"https:\/\/www.lymphoma.ca\/wp-content\/uploads\/2013\/04\/masthead_ph_shadows.jpg\",\"width\":700,\"height\":300},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.lymphoma.ca\/fr\/zydelig-idelalisib-recoit-lapprobation-par-sante-canada-pour-le-traitement-de-la-llc-et-du-lymphome-folliculaire\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.lymphoma.ca\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ZYDELIG (id\u00e9lalisib) re\u00e7oit l\u2019approbation par Sant\u00e9 Canada pour le traitement de la LLC et du lymphome folliculaire\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.lymphoma.ca\/fr\/#website\",\"url\":\"https:\/\/www.lymphoma.ca\/fr\/\",\"name\":\"Lymphoma Canada\",\"description\":\"Information. Help. Hope.\",\"publisher\":{\"@id\":\"https:\/\/www.lymphoma.ca\/fr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.lymphoma.ca\/fr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.lymphoma.ca\/fr\/#organization\",\"name\":\"Lymphoma Canada\",\"url\":\"https:\/\/www.lymphoma.ca\/fr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.lymphoma.ca\/fr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.lymphoma.ca\/wp-content\/uploads\/2023\/05\/logo-lymphoma.jpg\",\"contentUrl\":\"https:\/\/www.lymphoma.ca\/wp-content\/uploads\/2023\/05\/logo-lymphoma.jpg\",\"width\":343,\"height\":343,\"caption\":\"Lymphoma Canada\"},\"image\":{\"@id\":\"https:\/\/www.lymphoma.ca\/fr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/LymphomaCanada\",\"https:\/\/x.com\/lymphomacanada\",\"https:\/\/www.linkedin.com\/company\/lymphoma-canada\/\",\"http:\/\/instagram.com\/lymphomacanada\",\"http:\/\/www.youtube.com\/user\/LymphomaTV\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.lymphoma.ca\/fr\/#\/schema\/person\/3f654528f96ee33030061e70192633c4\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.lymphoma.ca\/fr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/f8f0e240f88d3162ad64d22cede41425?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/f8f0e240f88d3162ad64d22cede41425?s=96&d=mm&r=g\",\"caption\":\"admin\"},\"url\":\"https:\/\/www.lymphoma.ca\/fr\/author\/erezz_oxmaxp0p\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ZYDELIG (id\u00e9lalisib) re\u00e7oit l\u2019approbation par Sant\u00e9 Canada pour le traitement de la LLC et du lymphome folliculaire - Lymphoma Canada","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.lymphoma.ca\/fr\/zydelig-idelalisib-recoit-lapprobation-par-sante-canada-pour-le-traitement-de-la-llc-et-du-lymphome-folliculaire\/","og_locale":"fr_FR","og_type":"article","og_title":"ZYDELIG (id\u00e9lalisib) re\u00e7oit l\u2019approbation par Sant\u00e9 Canada pour le traitement de la LLC et du lymphome folliculaire - Lymphoma Canada","og_description":"Sant\u00e9 Canada approuve ZYDELIG (id\u00e9lalisib), de Gilead, pour le traitement de la leuc\u00e9mie lympho\u00efde chronique (LLC) r\u00e9cidivante et approuve ZYDELIG sous condition pour le traitement du lymphome folliculaire 8 avril...","og_url":"https:\/\/www.lymphoma.ca\/fr\/zydelig-idelalisib-recoit-lapprobation-par-sante-canada-pour-le-traitement-de-la-llc-et-du-lymphome-folliculaire\/","og_site_name":"Lymphoma Canada","article_publisher":"https:\/\/www.facebook.com\/LymphomaCanada","article_published_time":"2015-05-01T19:55:11+00:00","og_image":[{"width":700,"height":300,"url":"https:\/\/www.lymphoma.ca\/wp-content\/uploads\/2013\/04\/masthead_ph_shadows.jpg","type":"image\/jpeg"}],"author":"admin","twitter_card":"summary_large_image","twitter_creator":"@lymphomacanada","twitter_site":"@lymphomacanada","twitter_misc":{"\u00c9crit par":"admin","Dur\u00e9e de lecture estim\u00e9e":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.lymphoma.ca\/fr\/zydelig-idelalisib-recoit-lapprobation-par-sante-canada-pour-le-traitement-de-la-llc-et-du-lymphome-folliculaire\/#article","isPartOf":{"@id":"https:\/\/www.lymphoma.ca\/fr\/zydelig-idelalisib-recoit-lapprobation-par-sante-canada-pour-le-traitement-de-la-llc-et-du-lymphome-folliculaire\/"},"author":{"name":"admin","@id":"https:\/\/www.lymphoma.ca\/fr\/#\/schema\/person\/3f654528f96ee33030061e70192633c4"},"headline":"ZYDELIG (id\u00e9lalisib) re\u00e7oit l\u2019approbation par Sant\u00e9 Canada pour le traitement de la LLC et du lymphome folliculaire","datePublished":"2015-05-01T19:55:11+00:00","mainEntityOfPage":{"@id":"https:\/\/www.lymphoma.ca\/fr\/zydelig-idelalisib-recoit-lapprobation-par-sante-canada-pour-le-traitement-de-la-llc-et-du-lymphome-folliculaire\/"},"wordCount":253,"publisher":{"@id":"https:\/\/www.lymphoma.ca\/fr\/#organization"},"image":{"@id":"https:\/\/www.lymphoma.ca\/fr\/zydelig-idelalisib-recoit-lapprobation-par-sante-canada-pour-le-traitement-de-la-llc-et-du-lymphome-folliculaire\/#primaryimage"},"thumbnailUrl":"https:\/\/www.lymphoma.ca\/wp-content\/uploads\/2013\/04\/masthead_ph_shadows.jpg","articleSection":["Nouvelles"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.lymphoma.ca\/fr\/zydelig-idelalisib-recoit-lapprobation-par-sante-canada-pour-le-traitement-de-la-llc-et-du-lymphome-folliculaire\/","url":"https:\/\/www.lymphoma.ca\/fr\/zydelig-idelalisib-recoit-lapprobation-par-sante-canada-pour-le-traitement-de-la-llc-et-du-lymphome-folliculaire\/","name":"ZYDELIG (id\u00e9lalisib) re\u00e7oit l\u2019approbation par Sant\u00e9 Canada pour le traitement de la LLC et du lymphome folliculaire - Lymphoma Canada","isPartOf":{"@id":"https:\/\/www.lymphoma.ca\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.lymphoma.ca\/fr\/zydelig-idelalisib-recoit-lapprobation-par-sante-canada-pour-le-traitement-de-la-llc-et-du-lymphome-folliculaire\/#primaryimage"},"image":{"@id":"https:\/\/www.lymphoma.ca\/fr\/zydelig-idelalisib-recoit-lapprobation-par-sante-canada-pour-le-traitement-de-la-llc-et-du-lymphome-folliculaire\/#primaryimage"},"thumbnailUrl":"https:\/\/www.lymphoma.ca\/wp-content\/uploads\/2013\/04\/masthead_ph_shadows.jpg","datePublished":"2015-05-01T19:55:11+00:00","breadcrumb":{"@id":"https:\/\/www.lymphoma.ca\/fr\/zydelig-idelalisib-recoit-lapprobation-par-sante-canada-pour-le-traitement-de-la-llc-et-du-lymphome-folliculaire\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.lymphoma.ca\/fr\/zydelig-idelalisib-recoit-lapprobation-par-sante-canada-pour-le-traitement-de-la-llc-et-du-lymphome-folliculaire\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.lymphoma.ca\/fr\/zydelig-idelalisib-recoit-lapprobation-par-sante-canada-pour-le-traitement-de-la-llc-et-du-lymphome-folliculaire\/#primaryimage","url":"https:\/\/www.lymphoma.ca\/wp-content\/uploads\/2013\/04\/masthead_ph_shadows.jpg","contentUrl":"https:\/\/www.lymphoma.ca\/wp-content\/uploads\/2013\/04\/masthead_ph_shadows.jpg","width":700,"height":300},{"@type":"BreadcrumbList","@id":"https:\/\/www.lymphoma.ca\/fr\/zydelig-idelalisib-recoit-lapprobation-par-sante-canada-pour-le-traitement-de-la-llc-et-du-lymphome-folliculaire\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.lymphoma.ca\/fr\/"},{"@type":"ListItem","position":2,"name":"ZYDELIG (id\u00e9lalisib) re\u00e7oit l\u2019approbation par Sant\u00e9 Canada pour le traitement de la LLC et du lymphome folliculaire"}]},{"@type":"WebSite","@id":"https:\/\/www.lymphoma.ca\/fr\/#website","url":"https:\/\/www.lymphoma.ca\/fr\/","name":"Lymphoma Canada","description":"Information. Help. Hope.","publisher":{"@id":"https:\/\/www.lymphoma.ca\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.lymphoma.ca\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.lymphoma.ca\/fr\/#organization","name":"Lymphoma Canada","url":"https:\/\/www.lymphoma.ca\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.lymphoma.ca\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.lymphoma.ca\/wp-content\/uploads\/2023\/05\/logo-lymphoma.jpg","contentUrl":"https:\/\/www.lymphoma.ca\/wp-content\/uploads\/2023\/05\/logo-lymphoma.jpg","width":343,"height":343,"caption":"Lymphoma Canada"},"image":{"@id":"https:\/\/www.lymphoma.ca\/fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/LymphomaCanada","https:\/\/x.com\/lymphomacanada","https:\/\/www.linkedin.com\/company\/lymphoma-canada\/","http:\/\/instagram.com\/lymphomacanada","http:\/\/www.youtube.com\/user\/LymphomaTV"]},{"@type":"Person","@id":"https:\/\/www.lymphoma.ca\/fr\/#\/schema\/person\/3f654528f96ee33030061e70192633c4","name":"admin","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.lymphoma.ca\/fr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/f8f0e240f88d3162ad64d22cede41425?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/f8f0e240f88d3162ad64d22cede41425?s=96&d=mm&r=g","caption":"admin"},"url":"https:\/\/www.lymphoma.ca\/fr\/author\/erezz_oxmaxp0p\/"}]}},"_links":{"self":[{"href":"https:\/\/www.lymphoma.ca\/fr\/wp-json\/wp\/v2\/posts\/2310","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.lymphoma.ca\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.lymphoma.ca\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.lymphoma.ca\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.lymphoma.ca\/fr\/wp-json\/wp\/v2\/comments?post=2310"}],"version-history":[{"count":0,"href":"https:\/\/www.lymphoma.ca\/fr\/wp-json\/wp\/v2\/posts\/2310\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.lymphoma.ca\/fr\/wp-json\/wp\/v2\/media\/1772"}],"wp:attachment":[{"href":"https:\/\/www.lymphoma.ca\/fr\/wp-json\/wp\/v2\/media?parent=2310"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.lymphoma.ca\/fr\/wp-json\/wp\/v2\/categories?post=2310"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.lymphoma.ca\/fr\/wp-json\/wp\/v2\/tags?post=2310"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}